Reading the tape
NASDAQ: TECX
Tectonic Therapeutic, Inc.
Healthcare · Biotechnology
Market Cap
$549.59M
52w High
$36.03
52w Low
$14.39
P/E
-7.23
Volume
65.36K
Outstanding Shares
18.78M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 35.72%FCF (TTM): -1.86%
What changed
The stock rose 35.72% over the last year. Free cash flow declined 1.86% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs).
CEOAlise S. Reicin
SectorHealthcare
IndustryBiotechnology
Employees51
IPO dateJun 21, 2018
Valuation
Forward P/E—
EV/EBITDA-1.81
Enterprise value$129.69M
Stock splits
Jun 21, 2024↓ Reverse
Every 12 shares became 1
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-29.5%▲28.37%vs FY2024
Analyst consensus
RatingBuy
Target price$67.50▲130.61%
4
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$1.16 · Revenue est —
View